285 related articles for article (PubMed ID: 27001016)
1. The implications of ageing and life expectancy in prostate cancer treatment.
Kalra S; Basourakos S; Abouassi A; Achim M; Volk RJ; Hoffman KE; Davis JW; Kim J
Nat Rev Urol; 2016 May; 13(5):289-95. PubMed ID: 27001016
[TBL] [Abstract][Full Text] [Related]
2. Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer.
Bratt O; Folkvaljon Y; Hjälm Eriksson M; Akre O; Carlsson S; Drevin L; Franck Lissbrant I; Makarov D; Loeb S; Stattin P
Eur Urol; 2015 Jul; 68(1):53-8. PubMed ID: 25813688
[TBL] [Abstract][Full Text] [Related]
3. Management of older men with clinically localized prostate cancer: the significance of advanced age and comorbidity.
Hoffman KE
Semin Radiat Oncol; 2012 Oct; 22(4):284-94. PubMed ID: 22985811
[TBL] [Abstract][Full Text] [Related]
4. Point: the value of predicting life expectancy in men with clinically localized prostate cancer.
Clayton DB; Urban DA
J Natl Compr Canc Netw; 2007 Aug; 5(7):703-8. PubMed ID: 17692175
[TBL] [Abstract][Full Text] [Related]
5. [Competitive morbidity ant its impact on life expectancy: evaluation and inclusion in the therapeutic decision regarding localized prostatic cancer].
Soulié M; Villers A; Richaud P; Prapotnich D; Ruffion A; Grosclaude P
Prog Urol; 2001 Dec; 11(6):1195-204. PubMed ID: 11859652
[TBL] [Abstract][Full Text] [Related]
6. Predicting Life Expectancy in Men Diagnosed with Prostate Cancer.
Sammon JD; Abdollah F; D'Amico A; Gettman M; Haese A; Suardi N; Vickers A; Trinh QD
Eur Urol; 2015 Nov; 68(5):756-65. PubMed ID: 25819724
[TBL] [Abstract][Full Text] [Related]
7. Decision analyses in consideration of treatment strategies for patients with biochemical failure after curative therapy on clinically localized prostate cancer in the prostate-specific antigen era.
Shimizu F; Igarashi A; Fukuda T; Kawachi Y; Minowada S; Ohashi Y; Fujime M
Jpn J Clin Oncol; 2007 Oct; 37(10):763-74. PubMed ID: 17956899
[TBL] [Abstract][Full Text] [Related]
8. Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology.
Droz JP; Balducci L; Bolla M; Emberton M; Fitzpatrick JM; Joniau S; Kattan MW; Monfardini S; Moul JW; Naeim A; van Poppel H; Saad F; Sternberg CN
BJU Int; 2010 Aug; 106(4):462-9. PubMed ID: 20346033
[TBL] [Abstract][Full Text] [Related]
9. An analysis of watchful waiting for clinically localized prostate cancer.
Steinberg GD; Bales GT; Brendler CB
J Urol; 1998 May; 159(5):1431-6. PubMed ID: 9554328
[TBL] [Abstract][Full Text] [Related]
10. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
11. Patients' Survival Expectations With and Without Their Chosen Treatment for Prostate Cancer.
Xu J; Janisse J; Ruterbusch JJ; Ager J; Liu J; Holmes-Rovner M; Schwartz KL
Ann Fam Med; 2016 May; 14(3):208-14. PubMed ID: 27184990
[TBL] [Abstract][Full Text] [Related]
12. Clinical implementation of quality of life instruments and prediction tools for localized prostate cancer: results from a national survey of radiation oncologists and urologists.
Kim SP; Karnes RJ; Nguyen PL; Ziegenfuss JY; Han LC; Thompson RH; Trinh QD; Sun M; Boorjian SA; Beebe TJ; Tilburt JC
J Urol; 2013 Jun; 189(6):2092-8. PubMed ID: 23219546
[TBL] [Abstract][Full Text] [Related]
13. Personalized life expectancy and treatment benefit index of antiretroviral therapy.
Xiao Y; Sun X; Tang S; Zhou Y; Peng Z; Wu J; Wang N
Theor Biol Med Model; 2017 Jan; 14(1):1. PubMed ID: 28100241
[TBL] [Abstract][Full Text] [Related]
14. Calculating life expectancy to inform prostate cancer screening and treatment decisions.
Hawken SR; Auffenberg GB; Miller DC; Lane BR; Cher ML; Abdollah F; Cho H; Ghani KR;
BJU Int; 2017 Jul; 120(1):9-11. PubMed ID: 28199761
[No Abstract] [Full Text] [Related]
15. Questioning the 10-year Life Expectancy Rule for High-grade Prostate Cancer: Comparative Effectiveness of Aggressive vs Nonaggressive Treatment of High-grade Disease in Older Men With Differing Comorbid Disease Burdens.
Daskivich TJ; Lai J; Dick AW; Setodji CM; Hanley JM; Litwin MS; Saigal C;
Urology; 2016 Jul; 93():68-76. PubMed ID: 27079130
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of using guidelines to choose treatment for prostate cancer.
Mohan R; Beydoun H; Davis J; Lance R; Schellhammer P
Can J Urol; 2010 Feb; 17(1):4975-84. PubMed ID: 20156376
[TBL] [Abstract][Full Text] [Related]
17. Prognostic outlier genes for enhanced prostate cancer treatment.
Kim H; Skowronski J; Den RB
Future Oncol; 2017 Feb; 13(3):249-261. PubMed ID: 27728977
[TBL] [Abstract][Full Text] [Related]
18. A systematic literature review of life expectancy prediction tools for patients with localized prostate cancer.
Kent M; Vickers AJ
J Urol; 2015 Jun; 193(6):1938-42. PubMed ID: 25463998
[TBL] [Abstract][Full Text] [Related]
19. Cancer Screening in Older Adults.
Snyder AH; Magnuson A; Westcott AM
Med Clin North Am; 2016 Sep; 100(5):1101-10. PubMed ID: 27542429
[TBL] [Abstract][Full Text] [Related]
20. Cancer Screening in Older Patients.
Salzman B; Beldowski K; de la Paz A
Am Fam Physician; 2016 Apr; 93(8):659-67. PubMed ID: 27175838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
